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ess: tansu.ciftci@gazi.eSummary The mechanisms of nocturnal asthma are intimately related to circadian
rhythms, which influence inflammatory cells and mediators, hormone levels and
cholinergic tone. Nocturnal airway narrowing in asthma is sometimes associated with
sleep disorders, such as obstructive sleep apnea syndrome (OSAS). The aims of this
study were to evaluate the association of nocturnal asthma and OSAS, and
investigate the influence of continuous positive airway pressure (CPAP) therapy to
improve nighttime symptoms in asthmatic patients with OSAS. Forty-three asthmatic
patients who had nocturnal symptoms in spite of the optimal medical treatment
according to the Global Initiative for Asthma guidelines and associated with snoring
were studied. Pulmonary function tests (PFTs), asthma nighttime symptom scores,
and polysomnography were performed on all patients. We treated the patients with
an apnea-hypopnea index (AHI) X15 (moderate–severe OSAS) (n ¼ 16) with CPAP
during 2 months. After 2 months, PFT, asthma nighttime symptom scores were
reperformed. There was no significant difference in PFT values before and after
CPAP treatment in OSAS patients. Asthma nighttime symptom scores were improved
significantly (Po0.05) after CPAP treatment. In conclusion, in some patients with
nocturnal asthma, OSAS may be responsible disease for nocturnal symptoms. In this
condition, CPAP improves nocturnal symptoms without amelioration in PFT
abnormalities.
& 2004 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
12 2026119; fax: +90 312
du.tr (T.U. Ciftci).Introduction
Asthma is a chronic inflammatory disease of the
airways, characterized by hyperresponsiveness to aed.
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population at least sometime during their lives.1
Nocturnal asthma is not a different condition
from asthma and is defined as a variable nighttime
exacerbation of the underlying asthma condition
associated with increases in symptoms and need for
more medication, increased airway responsiveness
and/or worsening of lung function.2
The occurrence of nocturnal asthma is associated
with increased morbidity and inadequate of asthma
control. The mechanisms by which nocturnal
asthma develops remain unclear and may vary
from patient to patient.3 The main mechanism is
related to circadian rhythms. Most normal people
also have circadian changes in airway caliber with
mild nocturnal bronchoconstriction. Although cir-
cadian changes in flow rate are synchronous in
asthmatic patients and normal subjects, asthmatic
patients have a far greater variation in their peak
flow rates. Nocturnal bronchoconstriction in asth-
ma appears to be an exaggeration of the normal
circadian changes in airway caliber. Other factors
that have been proposed as possible causes for
overnight bronchoconstriction are interruption of
bronchodilator or other treatment, allergens in
bedding, airway cooling, supine posture, and
gastroesophageal reflux (GER). In addition, muco-
ciliary clearance is impaired during sleep, and the
accumulation of mucus in the airways could
contribute to nocturnal airway narrowing.4–6
Appropriate and adequate medical treatment
should be the first step for asthmatic patients with
nighttime symptoms. But, nighttime symptoms may
continue in some patients, against optimal medical
treatment. In this condition, other factors respon-
sible the nighttime symptoms should be investi-
gated. The relatively uncommon cause of nocturnal
asthma beyond ones mentioned above is obstruc-
tive sleep apnea syndrome (OSAS).
In present study, we aim to evaluate the associa-
tion of OSAS in asthmatic patients who had nighttime
symptoms in spite of the optimal medical treatment
and investigate the influence of continuous positive
airway pressure (CPAP) therapy to improve nighttime
symptoms in asthmatic patients with OSAS.Material method
Patient population
Study was performed on asthmatic patients who
had nighttime symptoms in spite of the optimal
medication according to Global Initiative for
Asthma (GINA) guidelines during 6 months andsuffered from habitual snoring. Patients with GER
symptoms were treated under the control of a
gastroenterologist during this period. Patients who
had nighttime symptoms after GER treatment were
included in the study.
Inclusion criteria: (1) At least one nocturnal
awakening or early morning awakening caused by
asthmatic symptoms (cough, wheeze, chest tight-
ness, and breathlessness) and (2) habitual snoring.
Patients with cardiac failure, cerebrovascular dis-
ease or a lung disease except asthma were excluded.
Two sleep studies were performed: one to assess
the diagnosis of OSAS and other to determine the
adequate pressure level of CPAP for patients with
OSAS. After diagnostic sleep study, patients with
sleep disorders except OSAS were excluded.
Patients were asked to check on the agenda when
they had nighttime symptoms each morning on
awakening during 2 months before and 2 months
after sleep studies.
All patients gave written informed consent to the
procedure. The study was carried out in accordance
with the Declarations of Helsinki.
Nocturnal asthma status
Physiologic parameters were expressed as the
patient’s best measure of forced expiratory volume
in first second (FEV1), forced vital capacity (FVC),
FEV1/FVC ratio, and forced expiratory flow be-
tween 25% and 75% of vital capacity (FEF25–75) in
percentage of the predicted value, measured with
a wedge spirometer, which fulfilled the require-
ments of the American Thoracic Society. Pulmonary
function test (PFT) was performed before sleep
study and after 2 months of CPAP treatment.
Nighttime symptoms were quantified as a score
according to the frequency of symptoms based on
GINA guidelines. According to patients’ agenda,
sums of the days with nighttime symptoms were
calculated and nocturnal asthma scores were
recorded as follows:0: No symptom,
1: p2 times a month,
2: 42 times a month,
3: o1 time a week,
4: Frequent.Sleep study
Overnight polysomnography (PSG) was performed
in all patients by a computerized system
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following variables: electrooculogram (two chan-
nels), electroencephalogram (four channels), elec-
tromyelogram of submental muscles (two
channels), electromyelogram of the anterior tibia-
lis muscle of both legs (two channels); electro-
cardiogram and airflow (with an oro-nasal
thermistor). Chest and abdominal efforts (two
channels) were recorded using inductive plethys-
mography, arterial oxyhemoglobin saturation
(SaO2: one channel) by pulse oximetry with a finger
probe. The recordings were conducted at a paper
speed of 10mm/s, and sleep stages were scored
according to the standard criteria of Rechtschaffen
and Kales.7 Arousals were scored according to
accepted definitions.8 Apneas were defined as
complete cessation of airflow X10 s. Hypopneas
were defined as a reduction of 450% in one of
three respiratory signals, airflow signal or either
respiratory or abdominal signals of respiratory
inductance plethysmography, with an associated
fell of X3% in oxygen saturation or an arousal. The
apnea-hypopnea index (AHI) was defined as the
number of apneas and hypopneas per hour of sleep.
Patients with AHIX5 were considered OSAS.
Patients were grouped by their total AHI. These
groups were AHI of 0–4.9 (normal), 5–14.9 (mild
OSAS), 15–29.9 (moderate OSAS), and X30 (severe
OSAS) as used in other studies.9 Those with AHI of
5–14.9 were followed with general recommenda-
tion such as weight loss, etc. Those with AHI ofX15
were offered a trial of nasal CPAP (nCPAP) treat-
ment and included in the subgroup of study.Nasal continuous positive airway pressure
study
The appropriate level of CPAP for each patient with
an AHIX15 was determined during an all-night
CPAP pressure determination study. A polysomno-
graphic study was performed with the same setup
as the diagnostic study, except that nCPAP was
applied during sleep. Attended CPAP titration was
performed with the CPAP auto-titrating device
(AutoSet; Resmed, Sydney, Australia) on the second
night of the study in our hospital. All patients were
prescribed the use CPAP device (Vector Plus CPAP
devices; Hoffrichter, Germany), which automati-
cally turned on when the mask was removed. Four
patients used CPAP with heated humidifier accord-
ing to their desire. We measured compliance by the
mean rate of CPAP use (hours per day). Acceptable
duration was considered X4 h/night. Optimal
medication according to GINA guidelines was
continued during CPAP treatment.Statistical analysis
Means and standard errors of measurement (SEM)
were determined for continuous variables and
percentage for categorical variables. Differences
in nighttime symptom scores and PFT values
between baseline and after CPAP treatment were
tested using the Wilcoxon signed-rank test. Differ-
ences between two groups were analyzed with the
Mann–Whitney U-test.
All statistical analyses were carried out using
statistical software (SPSS, version 11.0 for Win-
dows; SPSS Inc., Chicago, IL). Differences were
considered significant at Po0.05.Results
Forty-three asthmatic patients who had nighttime
symptoms in spite of the optimal medical treat-
ment according to the GINA guidelines and asso-
ciated with snoring were studied. According to PSG
data, 21 of 43 patients (48.83%) had OSAS with an
AHI45. Nineteen of 21 OSAS patients who had an
AHI415 were candidate for CPAP treatment.
Sixteen of 19 patients completed the study. The
reasons for the withdrawal of three patients were:
intolerance the CPAP treatment (one patient) and
insufficient duration of CPAP use (two patients).
Table 1 shows the demographics, PFT values,
SaO2, nighttime symptom scores, and diagnostic PSG
results for 43 patients included in the analysis. No
statistical differences were found in the two groups
(with and without OSAS) except for stages I and IV
percents. Stage I percents were found higher and
stage IV percents were found lower in asthmatic
patients with OSAS, comparing with patients without
asthma. Therefore, sleep is more superficial and
poorer in quality in asthmatics with OSAS.
Table 2 shows comparison of PFT values and
nighttime symptom scores at baseline and after
CPAP treatment of 16 OSAS patients. Nighttime
symptom scores were improved significantly after
CPAP treatment (scores were found lower after
CPAP in 10 patients comparing with scores before
CPAP, while were found higher in two patients and
found similar in four patients) (P ¼ 0:04). There
was no significant difference in PFT values before
and after CPAP treatment.Discussion
Nocturnal airway narrowing in asthma is often
associated with episodes of nocturnal and early
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Table 1 Demographics, PFT values, and diagnostic PSG results of the patients.
Patients without OSAS
(n ¼ 22)
Patients with OSAS (AHI415
and completed the study)
(n ¼ 16)
P-value
Age (years) 43.8678.32 45.9477.69 0.4
Sex (F/M) 19/13 9/7
Body mass index (kg/m2) 33.177.06 34.3876.08 0.39
FEV1 (% predicted) 65.52717.37 70.25721.17 0.61
FVC (% predicted) 83.21715.03 83.68717.93 0.85
FEV1/FVC 64.94714.3 66.68715.64 0.94
FEF25–75 (% predicted) 35.4716.72 39.87724.7 0.76
Nighttime symptom scores 1.7770.97 2.1971.07 0.22
AHI 3.973.72 44.25750.82 0.000*
Mean of the awakening SaO2
(%)
95.573.4 95.0672.64 0.28
Mean of the SaO2 during
sleep (%)
91.5476.2 89.0676.09 0.08
Mean of the minimum SaO2
during sleep (%)
82.3178.17 64.87720.37 0.003*
Stage I (%) 6.873.7 10.874.86 0.01*
Stage II (%) 37.95710.68 45.5679.5 0.06
Stage III (%) 5.1373.37 4.572.3 0.5
Stage IV (%) 7.6876.53 3.574.5 0.03*
REM (%) 14.0976.02 15.1276.3 0.8
Sleep efficiency (total sleep
time/total time in bed) (%)
68.86716.81 74.12713.9 0.35
Note: Values are mean7SD.
*Po0:05
Table 2 PFT values and nighttime symptoms scores of asthmatic patients with OSAS, before and after CPAP
treatment.
Baseline no. 16 After 2 months of CPAP treatment no. 16 P-value
FEV1 (% of predicted value) 70.25721.17 71.25721.85 0.64
FVC (% of predicted value) 83.68717.93 88.81720.64 0.34
FEV1/FVC 66.68715.64 70.75715.37 0.12
FEF25–75 (% of predicted value) 39.87724.7 40.4720.77 0.14
Nighttime symptom scores 2.1971.07 1.4471.15 0.04*
*Po0:05
T.U. Ciftci et al.532morning awakening, difficulty in maintaining sleep,
and daytime sleepiness. But, besides the impairing
of sleep quality by nocturnal asthma itself, an
association has been documented between noctur-
nal sleep-disordered breathing and asthma or
bronchial hyperreactivity.4,10–12 OSAS is the most
common sleep-disordered breathing and snoring is
one of the major symptoms of OSAS. While snoring
is present in more than 90% of the patients with
OSAS, OSAS can be determined in 8–10% of the
subjects with habitual snoring.1 In our study,
patients with both nocturnal asthma and snoring
were included and OSAS was identified in 21 of 43
(48.83%). This rate is higher than the OSAS rate
reported in healthy subjects with snoring andsuggests that OSAS may be one of the causes of
the nocturnal asthma, which is not improved with
medical treatment. Another important result of our
study was the improvement of nocturnal asthma
symptoms with CPAP. When the OSAS’s role on
development of nocturnal asthma is established,
the cause of its improvement with CPAP will also be
understood.
Several circadian rhythms may be important in
nocturnal asthma such as circadian changes in
bronchial hyperresponsiveness and inflamma-
tion.1,3,4,6,13 The changes in parasympathetic tonus
are responsible for the circadian changes in
bronchial hyperresponsiveness. Parasympathetic
tone is increased during sleep. The increase in
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receptors located in the central airways and
contribute to bronchoconstriction. Increased
parasympathetic bronchoconstrictor tone and
decreased nonadrenergic, noncholinergic broncho-
dilator function in the early morning may
significantly contribute to nocturnal asthma
exacerbations.3,4,13 On the other hand, patients
with OSAS have increased vagal tone during sleep.
It was documented that Muller maneuver was
involved in the development of the known sleep-
related hemodynamic changes noted with obstruc-
tive apnea or hypopnea. Atropine and other
anticholinergic medications, or autonomic nervous
system lesions eliminate the cardiovascular
changes associated with partial or complete upper
airway obstruction during sleep, which are
mediated through marked vagal stimulation. A
possibility exists that the increased vagal tone
could also produce bronchoconstriction. Guillemi-
nault et al.14 showed that combined with the local
effects of snoring, and increased vagal stimulation
would be a precipitating factor in nocturnal asthma
attacks and concluded that CPAP reduced vagal
tone in asthmatic patients with OSAS and this was
the cause for the improvement in their nocturnal
asthma.
According to another hypothesis suggested by
Chan et al.15 recurrent upper airway obstruction in
OSAS and snoring may be important triggering
mechanisms of nocturnal asthma attacks. The
recurrent episodes of airway obstruction and
snoring act as a chronic irritant that when
eliminated by CPAP therapy improved the asth-
matic symptoms. Neural receptors at the glottic
inlet and in the laryngeal region have been shown
to have potent bronchoconstrictive reflex activity.
Thus, with the repeated stimulation from snoring
and apnea of the oropharynx and glottic inlet or
larynx during the night, a neural reflex arc could be
initiated, producing bronchoconstriction. CPAP may
stabilize the upper airway and remove the chronic
nightly irritation to the oropharyngeal area, with
subsequent elimination of the reflex bronchocon-
striction.15 In another study suggesting that OSAS
can cause nocturnal asthma, Bohadana et al.16
reported that recurrent upper airway obstruction
causes bronchoconstriction by means of negative
intrathoracic pressure changes.
Chronic inflammation of the airway is the major
underlying mechanism of airway damage and
bronchoconstriction. Most importantly, bronchoal-
veolar lavage fluid in patients with nocturnal
asthma compared with asthma patients without
nighttime symptoms shows marked increase in
neutrophil and eosinophil counts at nighttime thanin the daytime. Patients with nocturnal asthma
seem to have more exaggerated inflammatory
response during the nighttime.4,6,13 Although the
pathogenesis of OSAS is not clearly understood,
various anatomic, mechanical, and neurologic,
components appear to contribute to relaxation
and closure of the pharyngeal airway during sleep.
Along with these, recently, upper airway inflamma-
tion has been suggested frequently in the patho-
genesis. Snoring is caused by vibration, which
occurs in uvula, soft palate and upper airway wall
while passing turbulent air into these tissues.
Inflammation and edema occur in upper airway
related to snoring and increasing upper airway
resistance. Moreover, Carpagnano et al.17 showed
the presence of an upper airway inflammation after
sleep in patients with OSAS correlated with severity
of the disease. On the other hand, in OSAS, cyclical
alterations of arterial oxygen saturation are ob-
served with oxygen desaturation developing in
response to apnea followed by the resumption of
oxygen saturation during hyperventilation. This
phenomenon has been referred to as hypoxia/
reoxygenation. Hypoxia functions as a danger signal
for the immune system by inducing the synthesis of
inflammatory cytokines. Some authors have re-
ported that systemic biomarkers of inflammation
has increased in patients with sleep apnea suggest-
ing a possible role in the pathologic consequences
of OSAS.18,19 This information demonstrates that,
inflammation exists in both asthma and OSAS, and
these two disorders may interact negatively.
Another issue needs attention in the matter of
association between nocturnal asthma and OSAS is
GER. Increased intrathoracic pressure caused by
upper airway obstruction in OSAS patients results in
GER through increasing pressure gradient between
stomach and eosephagus.1 On the other hand, in
GER, respiratory tract irritation resulted from
microaspiration of stomach content causes reflex
bronchoconstriction directly and acid irritation in
lower end of eosephagus by vagal pathway.20
Consequently, the hypothesis of OSAS causes GER
and GER causes nocturnal asthma can be proposed.
But, in our study, patients with GER symptoms were
received GER treatment along with asthma treat-
ment.
Present study showed that nocturnal asthma
symptoms could be treated with CPAP therapy
without amelioration on PFT values. Patients
included in our study have nocturnal symptoms in
spite of optimal medical treatment and OSAS was
identified in approximately half of these patients.
When considering OSAS is a disorder related to
sleep and influences only nocturnal symptoms
pertaining to asthma, nocturnal improvement with
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should be accepted logical. Being different from
our study, Chan et al.15 demonstrated that both
daytime and nighttime PEFR improved in patients
with concomitant OSAS and asthma when nocturnal
CPAP was applied. But, only nine subjects were
included in this study and asthma treatment given
together with CPAP did not mentioned.
On the other hand, it can be considered that, if
CPAP would improve nocturnal asthma in patients
without sleep apnea. The Martin and Pak21 study
showed that nCPAP was poorly tolerated in asth-
matic patients without concomitant sleep apnea
and did not improve nor lung function neither
nocturnal symptoms. CPAP given to patients with
nocturnal asthma who do not have OSAS does not
appear to be beneficial and was associated with
significant sleep disruption.
In present study, it is showed that 2 months of
CPAP treatment improved significantly nighttime
symptoms without changes in PFT values in patients
with nocturnal asthma associated OSAS. These
findings suggested that OSAS might be responsible
disease for nighttime symptoms. Further studies
are needed to investigate longtime effect of CPAP
treatment. In conclusion, it is important to enquire
as to the presence of symptoms of OSAS in patients
presenting with nocturnal asthma, because treat-
ment with CPAP may effect a substantial improve-
ment in asthma. Snoring in patients with asthma
raise clinical suspicion of OSAS but it must be
remembered that, excessive daytime sleepiness
resulted from poor quality sleeping due to noctur-
nal asthma symptoms is also an important symptom
of OSAS. In these conditions, PSG is the only
definitive way to document objective evidence of
OSAS and is also helpful in prescribing proper
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